Wen-Chin Ko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wen-Chin Ko has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Ling-Ping Lai
Division of Cardiology, Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan
5 shared publications - Chia-Ti Tsai
Cardiovascular Center, National Taiwan University Hospital , Taipei
4 shared publications - Ting-Lin Yen
Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
3 shared publications - Chih-Hao Yang
Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
2 shared publications - Chuang-Ye Hong
Department of Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
2 shared publications Eng-Thiam Ong
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in Redox Biology
- Vol. 98, 104453
Glial lipid reprogramming in brain aging: Lipid identity, organelle stress, and redox vulnerability
- 23 October 2026
- Published by Elsevier in Redox Biology
- Vol. 98, 104453
Open AccessGlial lipid reprogramming in brain aging: Lipid identity, organelle stress, and redox vulnerability
- Open Access
- 3 March 2026
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (4) , 1403-1417
Dapagliflozin Inhibits Thrombin Induced ADAM17 Phosphorylation and Downstream ERK/p-c-Jun-mediated CTGF Induction to Prevent Neointimal Hyperplasia
Vascular restenosis following angioplasty remains a major clinical challenge driven by excessive vascular smooth muscle cell (VSMC) migration, proliferation, and fibrosis. Thrombin, a potent signaling molecule beyond its coagulative function, promotes neointimal hyperplasia. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been shown to exert cardiovascular protection independent of its glucose-lowering effects, yet its role in thrombin-mediated fibrotic signaling remains unclear. Cultured A10 vascular smooth muscle cells were used to evaluate thrombin- stimulated A Disintegrin And Metalloprotease 17 (ADAM17), ERK1/2, c-Jun, and connective tissue growth factor (CTGF) by immunoblotting and migration analyses. Enzymatic activity (ADAM17 and thrombin) assays were tested by cell-free system kit. Pharmacological inhibition of ADAM17 by TAPI-1 and extracellular signal-regulated kinase (ERK) by U0126 were employed to delineate pathway hierarchy. An in vivo rat carotid artery balloon injury model was used to assess the effects of dapagliflozin on neointimal formation. Thrombin stimulation markedly increased ADAM17 phosphorylation, ERK1/2 and c-Jun activation, and CTGF expression in A10 cells. Dapagliflozin significantly suppressed these responses in a concentration-dependent manner without affecting thrombin enzymatic activity. Inhibition of ADAM17 recapitulated the effects of dapagliflozin, confirming ADAM17 as a key upstream mediator of thrombin-induced ERK/c-Jun/CTGF signaling. Functionally, dapagliflozin attenuated VSMC migration in vitro and significantly reduced neointimal hyperplasia in the rat carotid artery balloon injury model. Dapagliflozin inhibits thrombin-induced ADAM17 activation and downstream ERK1/2-c-Jun-CTGF signaling, thereby limiting VSMC migration and neointimal formation after vascular injury. This SGLT2-independent mechanism provides new insight into the pleiotropic vasculoprotective actions of dapagliflozin and identifies ADAM17 as a potential therapeutic target for preventing vascular restenosis and fibrosis-related cardiovascular disease.
- 3 March 2026
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 40 (4) , 1403-1417
Open AccessDapagliflozin Inhibits Thrombin Induced ADAM17 Phosphorylation and Downstream ERK/p-c-Jun-mediated CTGF Induction to Prevent Neointimal Hyperplasia
Vascular restenosis following angioplasty remains a major clinical challenge driven by excessive vascular smooth muscle cell (VSMC) migration, proliferation, and fibrosis. Thrombin, a potent signaling molecule beyond its coagulative function, promotes neointimal hyperplasia. Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been shown to exert cardiovascular protection independent of its glucose-lowering effects, yet its role in thrombin-mediated fibrotic signaling remains unclear. Cultured A10 vascular smooth muscle cells were used to evaluate thrombin- stimulated A Disintegrin And Metalloprotease 17 (ADAM17), ERK1/2, c-Jun, and connective tissue growth factor (CTGF) by immunoblotting and migration analyses. Enzymatic activity (ADAM17 and thrombin) assays were tested by cell-free system kit. Pharmacological inhibition of ADAM17 by TAPI-1 and extracellular signal-regulated kinase (ERK) by U0126 were employed to delineate pathway hierarchy. An in vivo rat carotid artery balloon injury model was used to assess the effects of dapagliflozin on neointimal formation. Thrombin stimulation markedly increased ADAM17 phosphorylation, ERK1/2 and c-Jun activation, and CTGF expression in A10 cells. Dapagliflozin significantly suppressed these responses in a concentration-dependent manner without affecting thrombin enzymatic activity. Inhibition of ADAM17 recapitulated the effects of dapagliflozin, confirming ADAM17 as a key upstream mediator of thrombin-induced ERK/c-Jun/CTGF signaling. Functionally, dapagliflozin attenuated VSMC migration in vitro and significantly reduced neointimal hyperplasia in the rat carotid artery balloon injury model. Dapagliflozin inhibits thrombin-induced ADAM17 activation and downstream ERK1/2-c-Jun-CTGF signaling, thereby limiting VSMC migration and neointimal formation after vascular injury. This SGLT2-independent mechanism provides new insight into the pleiotropic vasculoprotective actions of dapagliflozin and identifies ADAM17 as a potential therapeutic target for preventing vascular restenosis and fibrosis-related cardiovascular disease.
- Open Access
- 5 December 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (23) , 8729
Magnolol, A Novel Antagonist of Thrombin and PAR-1, Inhibits Thrombin-Induced Connective Tissue Growth Factor (CTGF) Expression in Vascular Smooth Muscle Cells and Ameliorate Pathogenesis of Restenosis in Rats
Restenosis and destructive vascular remodeling are the main reasons for treatment failure in patients undergoing percutaneous coronary intervention (PCI). In this study, we explored the efficacy of magnolol (a traditional Chinese medicine) in the treatment of restenosis. The results of this study showed that the activities of thrombin and PAR-1 (protease-activated receptor 1) were significantly decreased by the treatment of magnolol. Based on protein docking analysis, magnolol exhibits its potential to bind to the PAR-1 active site. In addition, thrombin-induced connective tissue growth factor (CTGF) expression and the upstream of CTGF such as JNK-1 (but not JNK-2), c-Jun, and AP-1 were distinctly inhibited by magnolol (50 μM) in vascular smooth muscle cells (VSMC). For the functional assay, magnolol (50 μM) significantly inhibited the migration of VSMC, and rats treated with magnolol (13 mg/kg/day) after balloon angioplasty has observed a significant reduction in the formation of common arterial neointima. In conclusion, we identified a novel mechanism by which magnolol acts as the thrombin activity inhibitor and may be the PAR-1 antagonist. In accordance with these functions, magnolol could decrease thrombin-induced CTGF expression in VSMCs via PAR-1/JNK-1/AP-1 signaling.
- 5 December 2020
- Published by MDPI AG in Applied Sciences
- Vol. 10 (23) , 8729
Open AccessMagnolol, A Novel Antagonist of Thrombin and PAR-1, Inhibits Thrombin-Induced Connective Tissue Growth Factor (CTGF) Expression in Vascular Smooth Muscle Cells and Ameliorate Pathogenesis of Restenosis in Rats
Restenosis and destructive vascular remodeling are the main reasons for treatment failure in patients undergoing percutaneous coronary intervention (PCI). In this study, we explored the efficacy of magnolol (a traditional Chinese medicine) in the treatment of restenosis. The results of this study showed that the activities of thrombin and PAR-1 (protease-activated receptor 1) were significantly decreased by the treatment of magnolol. Based on protein docking analysis, magnolol exhibits its potential to bind to the PAR-1 active site. In addition, thrombin-induced connective tissue growth factor (CTGF) expression and the upstream of CTGF such as JNK-1 (but not JNK-2), c-Jun, and AP-1 were distinctly inhibited by magnolol (50 μM) in vascular smooth muscle cells (VSMC). For the functional assay, magnolol (50 μM) significantly inhibited the migration of VSMC, and rats treated with magnolol (13 mg/kg/day) after balloon angioplasty has observed a significant reduction in the formation of common arterial neointima. In conclusion, we identified a novel mechanism by which magnolol acts as the thrombin activity inhibitor and may be the PAR-1 antagonist. In accordance with these functions, magnolol could decrease thrombin-induced CTGF expression in VSMCs via PAR-1/JNK-1/AP-1 signaling.
- Open Access
- 6 April 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (4) , 1100
Neuroprotective Effects of Platonin, a Therapeutic Immunomodulating Medicine, on Traumatic Brain Injury in Mice after Controlled Cortical Impact
Traumatic brain injury (TBI) is one of the leading causes of mortality worldwide and leads to persistent cognitive, sensory, motor dysfunction, and emotional disorders. TBI-caused primary injury results in structural damage to brain tissues. Following the primary injury, secondary injuries which are accompanied by neuroinflammation, microglial activation, and additional cell death subsequently occur. Platonin, a cyanine photosensitizing dye, has been used to treat trauma, ulcers, and some types of acute inflammation. In the present study, the neuroprotective effects of platonin against TBI were explored in a controlled cortical impact (CCI) injury model in mice. Treatment with platonin (200 µg/kg) significantly reduced the neurological severity score, general locomotor activity, and anxiety-related behavior, and improved the rotarod performance of CCI-injured mice. In addition, platonin reduced lesion volumes, the expression of cleaved caspase-3, and microglial activation in TBI-insulted brains. Platonin also suppressed messenger (m)RNA levels of caspase-3, caspase-1, cyclooxygenase-2, tumor necrosis factor-α, interleukin-6, and interleukin-1β. On the other hand, free radical production after TBI was obviously attenuated in platonin-treated mice. Treatment with platonin exhibited prominent neuroprotective properties against TBI in a CCI mouse model through its anti-inflammatory, anti-apoptotic, and anti-free radical capabilities. This evidence collectively indicates that platonin may be a potential therapeutic medicine for use with TBIs.
- 6 April 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (4) , 1100
Open AccessNeuroprotective Effects of Platonin, a Therapeutic Immunomodulating Medicine, on Traumatic Brain Injury in Mice after Controlled Cortical Impact
Traumatic brain injury (TBI) is one of the leading causes of mortality worldwide and leads to persistent cognitive, sensory, motor dysfunction, and emotional disorders. TBI-caused primary injury results in structural damage to brain tissues. Following the primary injury, secondary injuries which are accompanied by neuroinflammation, microglial activation, and additional cell death subsequently occur. Platonin, a cyanine photosensitizing dye, has been used to treat trauma, ulcers, and some types of acute inflammation. In the present study, the neuroprotective effects of platonin against TBI were explored in a controlled cortical impact (CCI) injury model in mice. Treatment with platonin (200 µg/kg) significantly reduced the neurological severity score, general locomotor activity, and anxiety-related behavior, and improved the rotarod performance of CCI-injured mice. In addition, platonin reduced lesion volumes, the expression of cleaved caspase-3, and microglial activation in TBI-insulted brains. Platonin also suppressed messenger (m)RNA levels of caspase-3, caspase-1, cyclooxygenase-2, tumor necrosis factor-α, interleukin-6, and interleukin-1β. On the other hand, free radical production after TBI was obviously attenuated in platonin-treated mice. Treatment with platonin exhibited prominent neuroprotective properties against TBI in a CCI mouse model through its anti-inflammatory, anti-apoptotic, and anti-free radical capabilities. This evidence collectively indicates that platonin may be a potential therapeutic medicine for use with TBIs.
- 27 December 2013
- Published by Wiley in Journal of Clinical Nursing
- Vol. 23 (13-14) , 2063-2073
The effectiveness of an accessibility‐enhanced multimedia informational educational programme in reducing anxiety and increasing satisfaction of patients undergoing cardiac catheterisation
Aims and objectives: To evaluate the effectiveness of an accessibility‐enhanced multimedia informational educational programme in reducing anxiety and increasing satisfaction with the information and materials received by patients undergoing cardiac catheterisation.Background: Cardiac catheterisation is one of the most anxiety‐provoking invasive procedures for patients. However, informational education using multimedia to inform patients undergoing cardiac catheterisation has not been extensively explored.Design: A randomised experimental design with three‐cohort prospective comparisons.Methods: In total, 123 consecutive patients were randomly assigned to one of three groups: regular education; (group 1), accessibility‐enhanced multimedia informational education (group 2) and instructional digital videodisc education (group 3). Anxiety was measured with Spielberger's State Anxiety Inventory, which was administered at four time intervals: before education (T0), immediately after education (T1), before cardiac catheterisation (T2) and one day after cardiac catheterisation (T3). A satisfaction questionnaire was administrated one day after cardiac catheterisation. Data were collected from May 2009–September 2010 and analysed using descriptive statistics, chi‐squared tests, one‐way analysis of variance, Scheffe's post hoc test and generalised estimating equations.Results: All patients experienced moderate anxiety at T0 to low anxiety at T3. Accessibility‐enhanced multimedia informational education patients had significantly lower anxiety levels and felt the most satisfied with the information and materials received compared with patients in groups 1 and 3. A statistically significant difference in anxiety levels was only found at T2 among the three groups (p = 0·004).Conclusions: The findings demonstrate that the accessibility‐enhanced multimedia informational education was the most effective informational educational module for informing patients about their upcoming cardiac catheterisation, to reduce anxiety and improve satisfaction with the information and materials received compared with the regular education and instructional digital videodisc education.Relevance to clinical practice: As the accessibility‐enhanced multimedia informational education reduced patient anxiety and improved satisfaction with the information and materials received, it can be adapted to complement patient education in future regular cardiac care.
- 27 December 2013
- Published by Wiley in Journal of Clinical Nursing
- Vol. 23 (13-14) , 2063-2073
The effectiveness of an accessibility‐enhanced multimedia informational educational programme in reducing anxiety and increasing satisfaction of patients undergoing cardiac catheterisation
Aims and objectives: To evaluate the effectiveness of an accessibility‐enhanced multimedia informational educational programme in reducing anxiety and increasing satisfaction with the information and materials received by patients undergoing cardiac catheterisation.Background: Cardiac catheterisation is one of the most anxiety‐provoking invasive procedures for patients. However, informational education using multimedia to inform patients undergoing cardiac catheterisation has not been extensively explored.Design: A randomised experimental design with three‐cohort prospective comparisons.Methods: In total, 123 consecutive patients were randomly assigned to one of three groups: regular education; (group 1), accessibility‐enhanced multimedia informational education (group 2) and instructional digital videodisc education (group 3). Anxiety was measured with Spielberger's State Anxiety Inventory, which was administered at four time intervals: before education (T0), immediately after education (T1), before cardiac catheterisation (T2) and one day after cardiac catheterisation (T3). A satisfaction questionnaire was administrated one day after cardiac catheterisation. Data were collected from May 2009–September 2010 and analysed using descriptive statistics, chi‐squared tests, one‐way analysis of variance, Scheffe's post hoc test and generalised estimating equations.Results: All patients experienced moderate anxiety at T0 to low anxiety at T3. Accessibility‐enhanced multimedia informational education patients had significantly lower anxiety levels and felt the most satisfied with the information and materials received compared with patients in groups 1 and 3. A statistically significant difference in anxiety levels was only found at T2 among the three groups (p = 0·004).Conclusions: The findings demonstrate that the accessibility‐enhanced multimedia informational education was the most effective informational educational module for informing patients about their upcoming cardiac catheterisation, to reduce anxiety and improve satisfaction with the information and materials received compared with the regular education and instructional digital videodisc education.Relevance to clinical practice: As the accessibility‐enhanced multimedia informational education reduced patient anxiety and improved satisfaction with the information and materials received, it can be adapted to complement patient education in future regular cardiac care.
- 3 January 2012
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 33 (1) , 49-56
Thrombin induced connective tissue growth factor expression in rat vascular smooth muscle cells via the PAR-1/JNK/AP-1 pathway
Aim: Methods: Results: Conclusion:
- 3 January 2012
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 33 (1) , 49-56
Thrombin induced connective tissue growth factor expression in rat vascular smooth muscle cells via the PAR-1/JNK/AP-1 pathway
Aim: Methods: Results: Conclusion:
- 1 July 2011
- Published by Elsevier in Heart Rhythm
- Vol. 8 (7) , 961-967
The biatrial substrate properties in different types of paroxysmal atrial fibrillation
- 1 July 2011
- Published by Elsevier in Heart Rhythm
- Vol. 8 (7) , 961-967
The biatrial substrate properties in different types of paroxysmal atrial fibrillation
- Open Access
- 1 January 2011
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 75 (7) , 1592-1600
Elevated Expression of Connective Tissue Growth Factor in Human Atrial Fibrillation and Angiotensin II-Treated Cardiomyocytes
Background: Atrial fibrosis is a feature of structural remodeling in atrial fibrillation (AF). Connective tissue growth factor (CTGF) is a potent profibrotic factor, but its role of CTGF in AF is not yet fully understood. Methods and Results: Right atrial appendages were obtained from 20 patients who underwent cardiac surgery (10 with sinus rhythm, 10 with AF). The mRNA level, protein level and immunohistochemical staining of CTGF were significantly increased in AF patients. In a porcine AF model, tissue angiotensin II (Ang II) and CTGF levels were significantly upregulated in both atria. In perfused rat hearts, Ang II stimulation increased CTGF expression, which could be inhibited by Ang II type I receptor antagonist. In a cell culture system, both atrial fibroblasts and myocytes were responsible for the increased CTGF expression under Ang II treatment. Ang II type I receptor antagonist could inhibit the Ang II-induced CTGF expression. Treating with recombinant CTGF, atrial fibroblasts expressed an increased level of collagen I. Furthermore, the CTGF level was highly correlated with tissue Ang II content in AF pigs. Conclusions: AF patients and animals exhibited a significantly increased expression of CTGF. Ang II stimulation upregulated CTGF expression in both atrial fibroblasts and myocytes. Ang II-induced CTGF expression might be involved in atrial substrate remodeling. (Circ J 2011; 75: 1592-1600)
- 1 January 2011
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 75 (7) , 1592-1600
Open AccessElevated Expression of Connective Tissue Growth Factor in Human Atrial Fibrillation and Angiotensin II-Treated Cardiomyocytes
Background: Atrial fibrosis is a feature of structural remodeling in atrial fibrillation (AF). Connective tissue growth factor (CTGF) is a potent profibrotic factor, but its role of CTGF in AF is not yet fully understood. Methods and Results: Right atrial appendages were obtained from 20 patients who underwent cardiac surgery (10 with sinus rhythm, 10 with AF). The mRNA level, protein level and immunohistochemical staining of CTGF were significantly increased in AF patients. In a porcine AF model, tissue angiotensin II (Ang II) and CTGF levels were significantly upregulated in both atria. In perfused rat hearts, Ang II stimulation increased CTGF expression, which could be inhibited by Ang II type I receptor antagonist. In a cell culture system, both atrial fibroblasts and myocytes were responsible for the increased CTGF expression under Ang II treatment. Ang II type I receptor antagonist could inhibit the Ang II-induced CTGF expression. Treating with recombinant CTGF, atrial fibroblasts expressed an increased level of collagen I. Furthermore, the CTGF level was highly correlated with tissue Ang II content in AF pigs. Conclusions: AF patients and animals exhibited a significantly increased expression of CTGF. Ang II stimulation upregulated CTGF expression in both atrial fibroblasts and myocytes. Ang II-induced CTGF expression might be involved in atrial substrate remodeling. (Circ J 2011; 75: 1592-1600)
- Open Access
- 1 January 2008
- Published by Medknow in Journal of Medical Ultrasound
- Vol. 16 (1) , 1-6
The Role of Echocardiography in Cardiac Resynchronization Therapy
For patients with medically refractive heart failure and wide QRS interval, cardiac resynchronization therapy has been established as an adjunctive therapy. Echocardiography is a useful method to identify and assess patients who are considered for cardiac resynchronization therapy and to determine the result after device implantation. This review article discusses the applications of echocardiography in patients receiving cardiac resynchronization therapy
- 1 January 2008
- Published by Medknow in Journal of Medical Ultrasound
- Vol. 16 (1) , 1-6
Open AccessThe Role of Echocardiography in Cardiac Resynchronization Therapy
For patients with medically refractive heart failure and wide QRS interval, cardiac resynchronization therapy has been established as an adjunctive therapy. Echocardiography is a useful method to identify and assess patients who are considered for cardiac resynchronization therapy and to determine the result after device implantation. This review article discusses the applications of echocardiography in patients receiving cardiac resynchronization therapy
- 7 March 2007
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 47 (3) , 397-403
Effects of the Angiotensin II Type 1 Receptor Antagonist Valsartan on the Expression of Superoxide Dismutase in Hypertensive Patients
The role of oxidative stress in the pathogenesis of vascular diseases such as hypertension has been well recognized. Angiotensin (Ang) II is regarded as a pro‐oxidant because it can stimulate the production of reactive oxygen species. The purpose of this study was to evaluate whether treatment with the Ang II type 1 (AT1) receptor antagonist valsartan has an antioxidant effect in patients with mild to moderate hypertension. A randomized, double‐blind, placebo‐controlled study was conducted in 48 stage I and II hypertensive subjects. Patients were followed every 4 weeks for 12 weeks after randomization to valsartan titrated to 80 to 160 mg once or twice daily or matching placebo. The erythrocyte superoxide dismutase (SOD) activity and expression of SOD–mRNA in polymorphonuclear leukocytes were measured before and after treatment. Valsartan showed concentration‐dependent inhibition of reactive oxygen species generation in polymorphonuclear leukocytes from hypertensive patients. The erythrocyte superoxide dismutase activity before treatment was more than 2 times higher in hypertensive subjects compared to normal controls. Superoxide dismutase activity decreased significantly after 12 weeks of treatment with valsartan but did not change with placebo. The amount of SOD‐mRNA in the polymorphonuclear leukocytes decreased progressively over 3 months in the hypertensive subjects receiving valsartan treatment but did not change in the placebo group. The production of reactive oxygen species is increased in hypertension, and superoxide dismutase activity is increased, presumably as a compensatory mechanism. Treatment with valsartan but not placebo resulted in a progressive down‐regulation of SOD‐mRNA expression and a reduction in superoxide dismutase activity, suggesting antioxidant activity and a reduction of reactive oxygen species generation. These findings imply that AT1 receptor antagonists may provide benefits to hypertensive patients beyond blood pressure reduction.
- 7 March 2007
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 47 (3) , 397-403
Effects of the Angiotensin II Type 1 Receptor Antagonist Valsartan on the Expression of Superoxide Dismutase in Hypertensive Patients
The role of oxidative stress in the pathogenesis of vascular diseases such as hypertension has been well recognized. Angiotensin (Ang) II is regarded as a pro‐oxidant because it can stimulate the production of reactive oxygen species. The purpose of this study was to evaluate whether treatment with the Ang II type 1 (AT1) receptor antagonist valsartan has an antioxidant effect in patients with mild to moderate hypertension. A randomized, double‐blind, placebo‐controlled study was conducted in 48 stage I and II hypertensive subjects. Patients were followed every 4 weeks for 12 weeks after randomization to valsartan titrated to 80 to 160 mg once or twice daily or matching placebo. The erythrocyte superoxide dismutase (SOD) activity and expression of SOD–mRNA in polymorphonuclear leukocytes were measured before and after treatment. Valsartan showed concentration‐dependent inhibition of reactive oxygen species generation in polymorphonuclear leukocytes from hypertensive patients. The erythrocyte superoxide dismutase activity before treatment was more than 2 times higher in hypertensive subjects compared to normal controls. Superoxide dismutase activity decreased significantly after 12 weeks of treatment with valsartan but did not change with placebo. The amount of SOD‐mRNA in the polymorphonuclear leukocytes decreased progressively over 3 months in the hypertensive subjects receiving valsartan treatment but did not change in the placebo group. The production of reactive oxygen species is increased in hypertension, and superoxide dismutase activity is increased, presumably as a compensatory mechanism. Treatment with valsartan but not placebo resulted in a progressive down‐regulation of SOD‐mRNA expression and a reduction in superoxide dismutase activity, suggesting antioxidant activity and a reduction of reactive oxygen species generation. These findings imply that AT1 receptor antagonists may provide benefits to hypertensive patients beyond blood pressure reduction.